

Quality Assurance Committee Report

Trust Board	Item: 18
Date: 1st December 2020	Enclosure: M
Purpose of the Report:	
This report has been produced for the Trust Board meeting to provide an update on discussions held at the Quality Assurance Committee in August 2020.	
FOR: Information <input checked="" type="checkbox"/> Assurance <input type="checkbox"/> Discussion and input <input type="checkbox"/> Decision/approval <input type="checkbox"/>	
Sponsor (Non-Executive Lead):	Dame Cathy Warwick Non-Executive Director
Author:	Dame Cathy Warwick Non-Executive Director
Author Contact Details:	c/o Susan Simpson, Director of Corporate Governance susan.simpson19@nhs.net
Risk Implications – Link to Assurance Framework or Corporate Risk Register:	Corporate quality and safety risks are recorded on the risk register
Legal / Regulatory / Reputation Implications:	CQC registration NHS Resolution CNST
Link to Relevant CQC Domain: All	
Safe <input checked="" type="checkbox"/> Effective <input checked="" type="checkbox"/> Caring <input checked="" type="checkbox"/> Responsive <input type="checkbox"/> Well Led <input type="checkbox"/>	
Link to Relevant Corporate Objective:	Strategic Objective 1: to deliver quality, patient centred healthcare services with and an excellent reputation.
Document Previously Considered By:	None
Recommendations:	
The Board is asked to note the content of this report for information.	

Quality Assurance Committee - 28th October 2020

Summary

Assurance was provided on clinical quality through a variety of data sources and discussion. The meeting was reduced in length due to service pressures.

Regular reports received and discussed for 'quality assurance and control' were:

- The September 2020 Integrated Performance and Operational Compliance Report (IPR)
- Reports related to Clinical Audit Report (Q1) , National Clinical Audit Exception Report(Q1), NICE guidance implementation report (Q1)

Verbal Reports were received on:

- Safer Staffing

The Committee noted:

- The Risk Register
- The SI report September 2020

Issues to note

Significant assurance was received in relation to:

- The continuing management of COVID alongside business as usual with excellent performance in relation to all cancer targets and elective work and the Winter Plan being signed off
- The majority of data contained within the integrated performance and operational compliance report
- The majority of clinical audits
- The continuation of transformation projects related to outpatients, flow and theatres
- The continuation of work on the quality priorities – reduction of PPH, delirium screening and end of life care- despite these priorities now continuing into 2021/22
- Staffing levels in the Trust

The Committee had some concerns in relation to mandatory training rates but received assurance that the most critical aspects of this e.g. infection prevention and control are now monitored via the daily COVID sit rep and that almost all mandatory training will soon be on line.

Pressure ulcer rates continue to cause concern but the Committee was assured that there is continued focus on this aspect of care which should translate to improvements in the November integrated performance report.

More information was asked for in relation to one high risk audit. The Committee sought assurance as to whether patients with early inflammatory arthritis were now being seen within the required timescale of three weeks as this had been raised as a problem when the clinical team presented to the Committee in December 2019.

In terms of good practice: as well as excellent performance on cancer targets generally and on reduction of elective waiting lists, the committee were delighted to note that patients diagnosed with lung cancer continue to receive excellent care as demonstrated by the National Lung Cancer Audit.